The role of neoadjuvant chemotherapy in advanced ovarian cancer: The right treatment to the right patient – Ensuring optimal outcomes in advanced ovarian cancer.

The article discusses the role of neoadjuvant chemotherapy (NAC) in advanced ovarian cancer (AOC) treatment, emphasizing the importance of surgery as a prognostic factor. It critiques the NAC/IDS approach, highlighting flaws in existing evidence and presenting the TRUST trial as a significant study involving fit patients from multiple countries. The debate surrounding NAC usage is addressed, acknowledging its benefits for specific patient populations while also recognizing potential misuse due to capacity and expertise limitations. [Extracted from the article]